
Resistance to antituberculous drugs among pulmonary tuberculous patients

Medhat El-Tabee El-Gohar

Tuberculosis is a disease that has been known since antiquity, and it remains one of the leading causes of morbidity and mortality worldwide. Its management has become more complex because of increased resistance to commonly used antituberculosis drugs. Tuberculosis (TB) is a major infectious disease killing nearly two million people, mostly in developing countries, every year. The increasing incidence of resistance of *Mycobacterium tuberculosis* strains to the most-effective (first-line) anti-TB drugs is a major factor contributing to the current TB epidemic. Drug-resistant strains have evolved mainly due to incomplete or improper treatment of TB patients. Resistance of *M. tuberculosis* to anti-TB drugs is caused by chromosomal mutations in genes encoding drug targets. Multidrug-resistant (resistant at least to rifampin and isoniazid) strains of *M. tuberculosis* (MDR-TB) evolve due to sequential accumulation of mutations in target genes. Emergence and spreading of MDR-TB strains is hampering efforts for the control and management of TB. The MDR-TB is also threatening World Health Organization's target of tuberculosis elimination by 2050. Proper management of MDR-TB relies on early recognition of such patients.¹¹⁵ Several diagnostic methods, both phenotypic and molecular, have been developed recently for rapid identification of MDR-TB strains from suspected patients and some are also suitable for resource-poor countries. Close contacts of MDR-TB patients are defined as people living in the same household or spending many hours a day together with the patient in the same indoor living space. The available data indicate that close contacts of MDR-TB patients who develop active TB most commonly have drug-resistant disease. Once identified, successful treatment of MDR-TB requires therapy with several effective drugs some of which are highly toxic, less efficacious and expensive. Proper drug susceptibility test, proper choice of drugs at the beginning of treatment and modification of treatment after knowing drug susceptibility testing results are important for the prevention of MDR-TB. Ensuring patient adherence to treatment is important in the medical institutions where drug susceptibility test is not properly done, in particular, for INH-resistant RMP-susceptible cases, and guidance to these institutions by the public health centers should be intensified. Minimum treatment duration of 18-24 months is also long, making it difficult for health care providers to ensure adherence to treatment. Successful treatment has been achieved by supervised therapy with appropriate drugs at institutions equipped with facilities for culture, drug susceptibility testing of MDR-TB strains to second-line drugs and

regular monitoring of patients for adverse drug reactions and bacteriological and clinical improvement.¹¹⁶ Conclusions from the present study, it was concluded that:

- Resistance to anti-tuberculous drugs is a major health threat in our country.
- The highest figures of resistance were to Isoniazid and Rifampicin which is probably attributed to the abuse of Rifampicin.
- The lowest figures of resistance were to Ethambutol.
- Resistance to drugs is very high among previously treated group.
- The most common type of resistance was acquired resistance because of lack of adherence to treatment or inappropriate treatment.
- MDR-TB is an increasing problem with higher figures of resistance in retreated patients.
- The more extensive the radiological lesion, the more incidence of resistance.
- The most common complications of anti-TB drugs was GIT manifestations and the least complications was electrolytes disturbance